COVID-19 associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges
journal contributionposted on 2022-03-15, 17:01 authored by Aia Mohamed, Thomas R Rogers, Alida TalentoAlida Talento
Aspergillus co-infection in patients with severe coronavirus disease 2019 (COVID-19) pneumonia, leading to acute respiratory distress syndrome, has recently been reported. To date, 38 cases have been reported, with other cases most likely undiagnosed mainly due to a lack of clinical awareness and diagnostic screening. Importantly, there is currently no agreed case definition of COVID-19 associated invasive pulmonary aspergillosis (CAPA) that could aid in the early detection of this co-infection. Additionally, with the global emergence of triazole resistance, we emphasize the importance of antifungal susceptibility testing in order to ensure appropriate antifungal therapy. Herein is a review of 38 published CAPA cases, which highlights the diagnostic and therapeutic challenges posed by this novel fungal co-infection.
CommentsThe original article is available at https://www.mdpi.com/
Published CitationMohamed A, Rogers TR, Talento AF. COVID-19 associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges J Fungi (Basel). 2020;6(3):115.
Publication Date22 July 2020
- Clinical Microbiology
- Published Version (Version of Record)
COVID-19 associated invasive pulmonary aspergillosisCOVID-19 pneumoniadiagnosisinvasive pulmonary aspergillosismulti-triazole resistanceCOVID-19CoronavirusSARS-CoV-2PandemicsAspergillusco-infectionacute respiratory distress syndrometriazole resistanceantifungal therapyRespiratory DiseasesInfectious Diseases